MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - May 30, 2012) - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
management will present at the upcoming Jefferies 2012 Global
Conference in New York.
Jefferies 2012 Global Healthcare Conference
Date: June 07, 2012, 01:00 pm EDT (07:00 pm CEST, 06:00 pm BST)
Venue: New York, USA
Participants: Dr. Simon Moroney, CEO of MorphoSys AG
Dr. Claudia Gutjahr-Löser, Head of Corporate
Communications & IR
The PDF version of the presentation will be provided at www.morphosys.com. A
link to the webcast is filed under www.morphosys.com/conference-calls.
On May 31, 2012, the Annual General Meeting 2012 of MorphoSys AG will take
in Munich. The management's presentation (in German) will be broadcast online
10:00 am CEST under www.morphosys.com/agm.
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
Company's AbD Serotec unit uses HuCAL and other technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the
pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more
70 human antibody drug candidates for the treatment of cancer, rheumatoid
arthritis, and Alzheimer's disease, to name just a few. With its ongoing
commitment to new antibody technology and drug development, MorphoSys is
on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt
Stock Exchange under the symbol MOR. For regular updates about MorphoSys,
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
and Ylanthia® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking statements
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE